Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 5/20 | 0.54 |
| ▸ | CDK8 | P49336 | 5/20 | 0.54 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.38 |
| ▸ | LPL | P06858 | 12/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | MYLK | Q15746 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | CILK1 | Q9UPZ9 | 1/20 | 0.36 |
| ▸ | CDK11A | Q9UQ88 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19656318 | 0.88 | CCNC (0.56) | CCNCCDK8LIPGLPLFLT3 | |
| SCHEMBL22448092 | 0.87 | LIPG (0.40) | CCNCCDK8LIPGLPLFFAR1 | |
| SCHEMBL19656349 | 0.86 | CCNC (0.39) | CCNCCDK8LIPGLPL | |
| SCHEMBL24896614 | 0.82 | AAK1 (0.39) | CCNCCDK8LIPGLPLFFAR1 | |
| SCHEMBL19656319 | 0.80 | CCNC (0.52) | CCNCCDK8LIPGLPLFLT3 | |
| SCHEMBL28877889 | 0.76 | S1PR1 (0.39) | CCNCCDK8LIPGLPLFFAR1 | |
| SCHEMBL26093683 | 0.76 | LIPG (0.39) | LIPGLPLFFAR1 | |
| SCHEMBL22448130 | 0.75 | CCNC (0.41) | CCNCCDK8LIPGLPLFFAR1 | |
| SCHEMBL26459129 | 0.75 | LIPG (0.37) | LIPGLPLFFAR1 | |
| SCHEMBL253500 | 0.74 | FFAR1 (0.57) | CCNCCDK8FLT3MYLKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11213520-B2 | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-04 | — | — | US | disclosed |
| US-20190290637-A1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213520-B2 | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors | CDK9, CDK19, CDK8 | CCNC 39/4885CDK8 3/4885LIPG 4695/4885 |
| US-20190290637-A1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | CDK9, CDK19, CDK8 | CCNC 39/4885CDK8 3/4885LIPG 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.